Pertussis Vaccine redefined
FDA is revising definition of pertussis vaccines to clarify that current licensure standards of production, reference, potency and toxicity are not applicable to acellular pertussis vaccines. FDA notes that it "is not proposing regulations for additional standards for the new acellular vaccines at this time." The final rule is effective as of publication in the Dec. 4 Federal Register. FDA notes that "clinical data and manufacturing specifications in [pending acellular] PLAs may support licensure in the near future".
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth